Abstract: Objective : To evaluate the therapeutic effect of cytokine-induced killer (CIK) cells in combination with dendritic cells on postoperative advanced gastric carcinoma. Methods : 110 patients with postoperative advanced gastric cancer were randomized into two groups. 1) The cellular im-munotherapy group consisted of 52 patients. Mononuclear cells from peripheral blood of the subjects were isolated and cultured with cytokines to produce mature DC and CIK-cells, and the autologous CIK cells were re-infused into the patients. DC were injected into groin, axillary lymph nodes, a subcuta-neous site near lymph nodes or intravenously. The patients were given approximately l.l-8.0xl0¹⁰ CIK cells and about 3-7xl0⁷ DC, two times per week, cycling for 4-6 weeks until all of the patients were given the second treatment consisting of chemotherapy. 2) All of the patients received chemotherapy consisting of CF+5 -FU +ADM+DDP. Three patients received 2 cycles, 6 received 3 cycles, forty-nine received more than 4 cycles. Results : In the group treated by cellular immunotherapy, the 3-year sur-vival rate was 86.8% (33/38)，and the 5-year survival rate was 78.9% (30/38). The 3-year survival rate of the chemotherapy group was 65.1% (28/43)，and the 5-year survival rate was 53.5% (23/43). The re-covery rate in high-CEA patients with immunotherapy was much higher than those with chemotherapy. Conclusion : Treatment with autologous -CIK cells in combination with dendritic cell therapy shows higher 3 -year and 5-year survival rates than routine chemotherapy for postoperative advanced gastric cancer patients. Immunotherapy improves cellular immune function and clinical symptoms without side effects. It is a safe and effective adjuvant therapy for advanced gastric carcinoma.